Hair Loss
Hair loss (telogen effluvium) is a frequently reported and anxiety-provoking side effect in retatrutide communities. This page explains the mechanism, what the clinical data shows, and what community claims get right and wrong.
Telogen effluvium is a well-documented consequence of rapid weight loss from any cause. It is typically temporary. Consult a dermatologist or physician if hair loss is severe or persistent.
Common Claims — Fact-Checked
These claims appear frequently in community discussions. Each is evaluated against the best available clinical evidence.
"Retatrutide causes hair loss."
?Context NeededHair loss (telogen effluvium) is reported in TRIUMPH trials and community discussions. However, it is a consequence of rapid weight loss — not a direct drug effect. Any intervention causing rapid weight loss (bariatric surgery, very low calorie diets) produces similar rates of telogen effluvium.
"Taking biotin prevents hair loss on retatrutide."
✗UnsupportedBiotin supplementation has no evidence for preventing telogen effluvium. The mechanism is physiological stress from rapid weight loss, not biotin deficiency. Hair typically regrows within 6–12 months as weight loss stabilizes.
Evidence Summary
Telogen effluvium: hair follicles enter a resting phase in response to physiological stress (rapid weight loss, surgery, illness). Shedding occurs 2–4 months after the stressor. Regrowth typically occurs within 6–12 months. TRIUMPH trial adverse event data includes alopecia as a reported event, consistent with the class.
Analyzed Threads
These threads were selected for editorial analysis. TryTrutide does not link to Reddit posts.
"Nausea is way worse than Ozempic — almost quit in week 2"
~Partially SupportedClaim: Users switching from semaglutide (Ozempic/Wegovy) to retatrutide report significantly worse nausea, particularly in the first 4–8 weeks, attributing this to the addition of glucagon receptor agonism.
The Phase 2 retatrutide trial reported nausea in 42% of participants on the 12 mg dose versus approximately 20–25% for semaglutide 2.4 mg in the STEP trials. The higher nausea rate is likely attributable to the triple agonist mechanism — glucagon receptor activation has independent emetic effects in addition to GLP-1-mediated nausea. However, direct head-to-head comparisons do not exist, and individual variation is substantial. The community observation of worse nausea than semaglutide is consistent with the clinical data, though the characterization of it being "way worse" reflects individual experience rather than a universal finding.
"Hair loss is real and nobody talks about it"
?Context NeededClaim: A significant number of users report noticeable hair shedding starting around weeks 8–16, attributed to retatrutide. Some claim it is worse than with semaglutide or tirzepatide.
Hair loss (telogen effluvium) is a well-documented consequence of rapid weight loss, not a direct drug effect. It occurs when the body redirects resources away from non-essential functions during caloric restriction. The same phenomenon is reported with semaglutide and tirzepatide. The TRIUMPH-Obesity trial listed alopecia as an adverse event in approximately 5% of participants on the 12 mg dose versus 1% on placebo — a real signal, but likely mediated by weight loss magnitude rather than the drug mechanism itself. Users losing weight faster with retatrutide may experience more pronounced telogen effluvium.
Reddit Observatory
26 topic categories — community claims vs. clinical evidence
Want a Physician to Review Your Eligibility?
Retatrutide is not yet FDA approved. A physician can review your health profile and discuss investigational access options.
Start Physician Review